Restricted accessReview articleFirst published online 2016-12
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms,neuropsychological functioning,and neuroimaging
In recent decades, the use of ayahuasca (AYA) – a β-carboline- and dimethyltryptamine-rich hallucinogenic botanical preparation traditionally used by Northwestern Amazonian tribes for ritual and therapeutic purposes – has spread from South America to Europe and the USA, raising concerns about its possible toxicity and hopes of its therapeutic potential. Thus, it is important to analyze the acute, subacute, and long-term effects of AYA to assess its safety and toxicity.
Objectives:
The purpose of this study was to conduct a systematic review of human studies assessing AYA effects on psychiatric symptoms, neuropsychological functioning, and neuroimaging.
Methods:
Papers published until 16 December 2015 were included from PubMed, LILACS and SciELO databases following a comprehensive search strategy and pre-determined set of criteria for article selection.
Results:
The review included 28 full-text articles. Acute AYA administration was well tolerated, increased introspection and positive mood, altered visual perceptions, activated frontal and paralimbic regions and decreased default mode network activity. It also improved planning and inhibitory control and impaired working memory, and showed antidepressive and antiaddictive potentials. Long-term AYA use was associated with increased cortical thickness of the anterior cingulate cortex and cortical thinning of the posterior cingulate cortex, which was inversely correlated to age of onset, intensity of prior AYA use, and spirituality. Subacute and long-term AYA use was not associated with increased psychopathology or cognitive deficits, being associated with enhanced mood and cognition, increased spirituality, and reduced impulsivity.
Conclusions:
Acute, subacute, and long-term AYA use seems to have low toxicity. Preliminary studies about potential therapeutic effects of AYA need replication due to their methodological limitations.
AlonsoJFRomeroSMañanasMÀ. (2015) Serotonergic psychedelics temporarily modify information transfer in humans. Int J Neuropsychopharmacol18: pii: pyv039.
2.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (4th ed. text revision). Washington, DC: American Psychiatric Association.
3.
Aricioglu-KartalFKayirH. (2003) Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Life Sci73: 2363–2371.
4.
BarbosaPCCazorlaIMGiglioJS. (2009) A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects. J Psychoactive Drugs41: 205–212.
5.
BarbosaPCGiglioJSDalgalarrondoP (2005) Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs37: 193–201.
6.
BarbosaPCMizumotoSBogenschutzMP. (2012) Health status of ayahuasca users. Drug Test Anal4: 601–609.
7.
BaumeisterDBarnesGGiaroliG. (2014) Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol4: 156–169.
8.
BogenschutzMPJohnsonMW (2016) Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry64: 250–258.
9.
BogenschutzMPPommyJM (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal4: 543–555.
10.
BogenschutzMPForcehimesAAPommyJA. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
11.
BousoJCRibaJ (2011) An overview of the literature on the pharmacology and neuropsychiatric long term effects of ayahuasca. In: Dos SantosRG (ed) The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network, pp. 55–63.
12.
BousoJCFábregasJMAntonijoanRM. (2013) Acute effects of ayahuasca on neuropsychological performance: Differences in executive function between experienced and occasional users. Psychopharmacology230: 415–424.
13.
BousoJCGonzálezDFondevilaS. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. PLoS One7: e42421.
14.
BousoJCPalhano-FontesFRodríguez-FornellsA. (2015) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol25: 483–492.
15.
BrierleyDIDavidsonC (2013) Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. J Psychopharmacol27: 98–108.
16.
CakicVPotkonyakJMarshallA (2010) Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users. Drug Alcohol Depend111: 30–37.
17.
CallawayJCGrobCS (1998) Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. J Psychoactive Drugs30: 367–369.
18.
Carhart-HarrisRLErritzoeD. (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A109: 2138–2143.
19.
Carhart-HarrisRLLeechRErritzoeD. (2013) Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull39: 1343–1351.
20.
Carhart-HarrisRLLeechRHellyerPJ. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci8: 20.
21.
Carhart-HarrisRLLeechRWilliamsTM. (2012b) Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry200: 238–244.
22.
CarterOLBurrDCPettigrewJD. (2005a) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci17: 1497–1508.
23.
CarterOLPettigrewJDBurrDC. (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport15: 1947–1951.
24.
CarterOLPettigrewJDHaslerF. (2005b) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology30: 1154–1162.
25.
CohenS (1960) Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis130: 30–40.
26.
CohenSDitmanKS (1962) Complications associated with lysergic acid diethylamide (LSD-25). J Am Med Assoc181: 161–162.
27.
Da SilveiraDXGrobCSDe RiosMD. (2005) Ayahuasca in adolescence: A preliminary psychiatric assessment. J Psychoactive Drugs37: 129–133.
28.
DamásioA (2000) O mistério da consciência – do corpo e das emoções ao conhecimento de si [The feeling of what happens – body and emotion in the making of consciousness]. São Paulo: Companhia das Letras.
29.
DaumannJHeekerenKNeukirchA. (2008) Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology200: 573–583.
30.
DaumannJWagnerDHeekerenK. (2010) Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol24: 1515–1524.
31.
De AraujoDBRibeiroSCecchiGA. (2012) Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Hum Brain Mapp33: 2550–2560.
32.
Doering-SilveiraELopezEGrobCS. (2005a) Ayahuasca in adolescence: A neuropsychological assessment. J Psychoactive Drugs37: 123–128.
33.
Doering-SilveiraEGrobCSDe RiosMD. (2005b) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs37: 141–144.
34.
Dos SantosRG (2010) Toxicity of chronic ayahuasca administration to the pregnant rat: How relevant it is regarding the human, ritual use of ayahuasca?Birth Defects Res B Dev Reprod Toxicol89: 533–535.
35.
Dos SantosRG (2011) Possible risks and interactions of the consumption of ayahuasca and cannabis in humans. In: Dos SantosRG (ed) The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network, pp. 87–95.
36.
Dos SantosRG (2013a) Safety and side effects of ayahuasca in humans – An overview focusing on developmental toxicology. J Psychoactive Drugs45: 68–78.
37.
Dos SantosRG (2013b) A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J Psychoactive Drugs45: 179–188.
Dos SantosRGGrasaEValleM. (2012) Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology219: 1039–1053.
40.
Dos SantosRGLandeira-FernandezJStrassmanRJ. (2007) Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol112: 507–513.
41.
Dos SantosRGOsórioFLCrippaJAS. (2016) Letter to the editor. J Forensic Leg Med38: 116–117.
42.
Dos SantosRGOsórioFLCrippaJAS. (2016) Antidepressive and anxiolytic effects of ayahuasca: A systematic literature review of animal and human studies. Rev Bras Psiquiatr38: 65–72.
43.
Dos SantosRGValleMBousoJC. (2011) Autonomic, neuroendocrine and immunological effects of ayahuasca. A comparative study with d-amphetamine. J Clin Psychopharmacol31: 717–726.
44.
FábregasJMGonzálezDFondevilaS. (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend111: 257–261.
45.
FernándezXFábregasJM (2014) Experience of treatment with ayahuasca for drug addiction in the Brazilian Amazon. In: LabateBCCavnarC (eds) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag, pp. 161–182.
46.
FernándezXDos SantosRGCutchetM. (2014) Assessment of the psychotherapeutic effects of ritual ayahuasca use on drug dependency: A pilot study. In: LabateBCCavnarC (eds) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag, pp. 183–196.
47.
FortunatoJJRéusGZKirschTR. (2009) Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry33: 1425–1430.
48.
FortunatoJJRéusGZKirschTR. (2010) Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in the rat hippocampus. J Neural Transm117: 1131–1137.
49.
FrecskaE (2008) Ayahuasca versus violence – a case report. Neuropsychopharmacol Hung10: 103–106.
50.
FrecskaELunaLE (2006) The adverse effects of hallucinogens from intramural perspective. Neuropsychopharmacol Hung8: 189–200.
51.
FrecskaEMóréCEVarghaA. (2012) Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs44: 191–199.
52.
FrecskaEWhiteKDLunaLE (2004) Effects of ayahuasca on binocular rivalry with dichoptic stimulus alternation. Psychopharmacology173: 79–87.
53.
GableRS (2007) Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction102: 24–34.
54.
GasserPHolsteinDMichelY. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513–520.
GlickSDKuehneMERaucciJ. (1994) Effects of iboga alkaloids on morphine and cocaine self-administration in rats: Relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res657: 14–22.
57.
GogtayNGieddJNLuskL. (2004) Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A101: 8174–8179.
58.
González-MaesoJSeafonSC (2009) Psychedelics and schizophrenia. Trends Neurosci32: 225–232.
59.
GrobCSDanforthALChopraGS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
60.
GrobCSMcKennaDJCallawayJC. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis184: 86–94.
61.
GroismanA (2000) Santo Daime in the Netherlands: An anthropological study of a new world religion in a European setting. PhD Thesis, University of London, UK.
62.
HalpernJHSherwoodARHudsonJI. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry58: 624–631.
63.
HalpernJHSherwoodARPassieT. (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit14: SR15–22.
64.
HaslerFGrimbergUBenzMA. (2004) Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology172: 145–156.
65.
HeekerenKDaumannJNeukirchA. (2008) Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology199: 77–88.
66.
HeekerenKNeukirchADaumannJ. (2007) Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol21: 312–320.
67.
HermleLFünfgeldMOepenG. (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol Psychiatry32: 976–991.
68.
HollisterLESjobergBM (1964) Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin and a combination of the three psychotomimetic drugs. Compr Psychiatry5: 170–178.
69.
JohnsonMWGarcia-RomeuACosimanoMP. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
70.
KometerMSchmidtABachmannR. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry72: 898–906.
71.
KraehenmannRPrellerKHScheideggerM. (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry78: 572–581.
72.
LabateBC (2011) Consumption of ayahuasca by children and pregnant women: Medical controversies and religious perspectives. J Psychoactive Drugs43: 27–35.
73.
LabateBCAraújoWS (eds) (2004) O Uso Ritual da Ayahuasca. Campinas: Mercado das Letras.
74.
LabateBCCavnarC (eds) (2014) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag.
75.
LabateBCDos SantosRGStrassmanR. (2014) Effect of Santo Daime membership on substance dependence. In: LabateBCCavnarC (eds) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag, pp. 153–159.
76.
LabateBCRoseISDos SantosRG (2009) Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays. Santa Cruz: Multidisciplinary Association for Psychedelic Studies.
77.
LiesterMBPrickettJI (2012) Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J Psychoactive Drugs44: 200–208.
78.
LimaFASTófoliLF (2011) An epidemiological surveillance system by the UDV: Mental health recommendations concerning the religious use of hoasca. In: LabateBCJungaberleH (eds) The Internationalization of Ayahuasca. Zurich: Lit Verlag, pp. 185–199.
79.
Loizaga-VelderALoizaga PazziA (2014) Therapist and patient perspectives on ayahuasca-assisted treatment for substance dependence. In: LabateBCCavnarC (eds) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag, pp. 133–152.
80.
Loizaga-VelderAVerresR (2014) Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence-qualitative results. J Psychoactive Drugs46: 63–72.
81.
McKennaDJTowersGHAbbottF (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of ayahuasca. J Ethnopharmacol10: 195–223.
82.
MacRaeE (1998) Santo Daime and Santa Maria – The licit ritual use of ayahuasca and the illicit use of cannabis in a Brazilian Amazonian religion. Int J Drug Policy9: 325–338.
83.
MallesonN (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry118: 229–230.
84.
MasonMFNortonMIVan HornJD. (2007) Wandering minds: The default network and stimulus-independent thought. Science315: 393–395.
85.
MoherDLiberatiATetzlaffJ.; The PRISMA Group. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med6: e1000097.
86.
MorenoFAWiegandCBTaitanoEK. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry67: 1735–1740.
87.
MorenoJLHollowayTRayannavarV. (2013) Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice. Neurosci Lett536: 69–73.
88.
MuthukumaraswamySDCarhart-HarrisRLMoranRJ. (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci33: 15171–15183.
89.
OliveiraCDMoreiraCQde SáLR. (2010) Maternal and developmental toxicity of ayahuasca in Wistar rats. Birth Defects Res B Dev Reprod Toxicol89: 207–212.
90.
Oliveira-LimaAJSantosRHollaisAW. (2015) Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice. Physiol Behav142: 28–36.
91.
OsórioFLSanchesRFMacedoLRH. (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev Bras Psiquiatr37: 13–20.
92.
OwaisatSRaffaRBRawlsSM (2012) In vivo comparison of harmine efficacy against psychostimulants: Preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett525: 12–16.
93.
Palhano-FontesFAndradeKCTofoliLF. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One10: e0118143.
94.
PanziniRGda RochaNSBandeiraDR. (2007) Quality of life and spirituality. Rev Psiquiatr Clín34: S105–S115.
95.
Pic-TaylorAMottaLGMoraisJA. (2015) Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. Behav Processes118: 102–110.
96.
RibaJAndererPJanéF. (2004) Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology50: 89–101.
97.
RibaJAndererPMorteA. (2002a) Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Psychol53: 613–628.
98.
RibaJMcIlhennyEHBousoJC. (2015) Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: A comparative study. Drug Test Anal7: 401–406.
99.
RibaJRodríguez-FornellsABarbanojMJ (2002b) Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology165: 18–28.
100.
RibaJRodríguez-FornellsAUrbanoG. (2001) Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology154: 85–95.
101.
RibaJRomeroSGrasaE. (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology186: 93–98.
102.
RibaJValleMUrbanoG. (2003) Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther306: 73–83.
103.
RossS (2012) Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am35: 357–374.
104.
SamoylenkoVRahmanMMTekwaniBL. (2010) Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J Ethnopharmacol127: 357–367.
105.
SanchesRFOsórioFLDos SantosRG. (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. J Clin Psychopharmacol36: 77–81.
106.
SchaferDPLehrmanEKKautzmanAG. (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron74: 691–705.
107.
SchenbergEEAlexandreJFFilevR. (2015) Acute biphasic effects of ayahuasca. PLoS One10: e0137202.
108.
SchmidYEnzlerFGasserP. (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry78: 544–553.
109.
SchultesREHofmannA (1992) Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Rochester: Healing Arts Press.
110.
SchwarzMJHoughtonPJRoseS. (2003) Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav75: 627–633.
111.
SmartRGBatemanK (1967) Unfavourable reactions to LSD: A review and analysis of the available case reports. Can Med Assoc J97: 1214–1221.
112.
SolerJElicesMFranquesaA. (2015) Exploring the therapeutic potential of ayahuasca: Acute intake increases mindfulness-related capacities. Psychopharmacology233: 823-829.
113.
SteedsHCarhart-HarrisRLStoneJM (2015) Drug models of schizophrenia. Ther Adv Psychopharmacol5: 43–58.
114.
StrassmanRJ (1984) Adverse reactions to psychedelic drugs: A review of the literature. J Nerv Ment Dis172: 577–595.
115.
StrassmanRJQuallsCRUhlenhuthEH. (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry51: 98–108.
116.
StuderusEKometerMHaslerF. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol25: 1434–1452.
117.
SzmulewiczAGValerioMPSmithJM (2015) Switch to mania after ayahuasca consumption in a man with bipolar disorder: A case report. Int J Bipolar Disord3: 4.
118.
ThomasGLucasPCaplerNR. (2013) Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev6: 30–42.
119.
UmbrichtDVollenweiderFXSchmidL. (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: Implications for the neuropharmacology of cognitive deficits in schizophrenia.Neuropsychopharmacology28: 170–181.
120.
United Nations Office on Drugs and Crime (2014) World Drug Report 2014. New York: United Nations.
121.
VollenweiderFXGeyerMA (2001) A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull56: 495–507.
122.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci11: 642–651.
123.
VollenweiderFXLeendersKLScharfetterC. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology16: 357–372.
124.
VollenweiderFXVollenweider-ScherpenhuyzenMFBäblerA. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport9: 3897–3902.
125.
WinkelmanM (2014) Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Curr Drug Abuse Rev7: 101–116.
126.
WittmannMCarterOHaslerF. (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol21: 50–64.
